August 2024 | AIChE

You are here

August 2024

Technical Program

Technical Program (this program is subject to change) Confex program Day 1 - October 28, 2024 Start Time End Time 8:30 AM 9:30 AM Registration (open all day) 9:30 AM 9:40 AM Morning Welcome 9:40 AM 10:50 AM Session 1 - Advances in Cellular Immunotherapy 9:40 AM 10:10 AM Umoja's Make vs Buy decision...

Damien Fink



Damien currently leads the Analytical Development group at Century Therapeutics. He’s a graduate (and avid fan) of Pennsylvania State University and Villanova University. His experience in Analytical Development stems from his tenure at Merck Manufacturing Division (4+ years) and Janssen R&D (16+ years) where he worked extensively on assay development and validation efforts in both the GMP and GLP space relating to products such as Recombivax HB, Vaqta, Gardasil, golimumab, amivantamab, teclistamab, talquetamab, and ciltacabtagene autoleucel among many others. In his...Read more

Peter Deak



Dr. Peter Deak is an assistant professor of Chemical and Biological Engineering who joined the department in August 2022.  He received his BS in Chemical Engineering from the University of Dayton (Dayton, OH) and his MS in Chemical Engineering and PhD in Bioengineering from the University of Notre Dame working under Dr. Basar Bilgicer.  His PhD work was designing novel diagnostics and therapeutics for food allergies. After his PhD, Dr. Deak worked in the Pritzker School of Molecular Engineering at the University of Chicago working under Dr. Aaron Esser-Kahn,...Read more

Sangwook Choi



Sangwook Choi is based in Seattle, WA and works in the CMC (Chemistry, Manufacturing and Controls) Biostatistics group supporting the Cell Therapy Development and Operations Organization at Bristol Myers Squibb (BMS). He originally joined Juno Therapeutics in 2016 which got acquired by Celgene, and he has worked at BMS since 2019 as a result of the Celgene-BMS integration. Prior to joining BMS, Sangwook had worked at Samsung Electronics and a biotech start-up company. Sangwook holds a Ph.D. in Chemical and Biomolecular Engineering from University of Illinois at Urbana and...Read more

Brian Lowry

Brian Lowry is a Principal Research Scientist II in Purification Development within AbbVie S&T Biologics.

Brian has 9+ years of experience at AbbVie in pharmaceutical drug substance process development, spanning both synthetic small molecule and biologics development.

At AbbVie, he has supported the development of multiple late-stage drug substance programs (small molecule APIs and biologics) and contributed to their NDA and BLA regulatory filings. In his current role, he is leading a team of scientists supporting AbbVie’s early phase, pre-IND biologics programs.

...Read more

Nil Tandogan-Gray

Nil Tandogan Gray received her double BSc in Chemical Engineering and Biology from Middle East Technical University in Ankara, Turkiye, and completed her PhD in Chemical Engineering at Northeastern University in Boston in 2016. After graduation, Nil joined Synthetic Molecule Design and Development (SMDD) at Eli Lilly and Company as a process engineer. Within SMDD, her work focused on DS process development of peptide assets, and establishment and execution of new platforms for manufacturing .

In 2021, Nil joined the rotational program within Lilly and completed two one-year...Read more

Pages